gene_symbol
MAGEA3
hgnc_id
HGNC:6801
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Acts as an in situ vaccine: peptide coating drives DC cross-priming and expansion of MAGE-A3–specific CD8+ T cells that kill MAGE-A3+ tumor cells via cytotoxic T-lymphocyte mechanisms; viral oncolysis is not MAGE-A3-specific.
enzyme_product
Off
epitope
On
variant
Off
isoform
Off
hla_specific
Off
gated
Off
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05492682
disease_id_num_tar_ref
5312
drug_id_num_tar_ref
14448